Recently published epidemiology studies showed that lung cancer occupies the leading position for both estimated deaths and new cases of human cancer in the United States and China.
for advanced cases, the prognosis of NSCLC is still poor, and the 5-year survival rate remains below 15%. 3 Therefore, it is critical to identify the mechanisms of NSCLC development and explore innovative therapies for NSCLC patients.
MicroRNAs (miRNAs) are a group of highly conserved small noncoding RNAs with lengths of 20-24 nucleotides. 4 As a rule, miRNAs can repress mRNA translation or promote RNA degradation by binding to the 3′-UTRs of their targets. 5 Numerous pieces of evidence
show that abnormal expression of miRNAs and their regulation play important roles in the initiation and progression of human cancers, such as esophageal carcinoma, 6 ,7 hepatocellular carcinoma 8 and breast carcinoma. 9 Some miRNAs, such as miR-30a, are able to affect many types of malignancies and can be used as biomarkers for these tumors. 10 To date, multiple miRNAs have been shown to have vital functions in the development of NSCLC, 11, 12 but few of these miRNAs could be a candidate for targeted therapy, 13 and the specific underlying mechanisms for their effects in the tumorigenesis and progression of NSCLC are still not understood.
MicroRNA-331-3p is a miRNA that was reported to be abnormally expressed in several cancer types. However, the effect of miR-331-3p in different cancer types completely varies.
MiR-331-3p
functions as an oncogene in pancreatic cancer 14 and hepatocellular cancer, 15 but as a tumor suppressor gene in gastric cancer 16 and cervical cancer. 17 Although these studies described the effects of miR-331-3p in different types of cancer, the biological functions of miR-331-3p in NSCLC are still unknown. Herein, we found that the expression level of miR-331-3p was significantly lower in NSCLC tumor tissues than in adjacent normal tissues and negatively correlated with advanced stage and lymph node metastasis of NSCLC.
Overexpression of miR-331-3p repressed the epithelial-mesenchymal transition (EMT) phenotype, migratory capacity, and metastatic ability of NSCLC cells in vitro and vivo. Moreover, ErbB2 and VAV2
were identified as the target mRNAs of miR-331-3p, and the ErbB2/ VAV2 complex and downstream Rac1/PAK1/β-catenin activity were shown to be downregulated by miR-331-3p. Our findings confirmed the tumor suppressor activity of miR-331-3p in NSCLC and showed that VAV2 is a novel target of miR-331-3p.
| MATERIAL S AND ME THODS

| Ethics approval and consent to participate
This study was approved by the ethics committee of Xiangya Hospital, Central South University (CSU; Changsha, China), and written informed consent was obtained from all patients. All animal studies were approved by the Animal Ethics Committee and undertaken in accordance with the official recommendations of the Care and
Use of Laboratory Animals of Xiangya Hospital, CSU.
| Patients and tissue specimens
From January 2011 to December 2012, a total of 80 pairs of NSCLC tumor tissues and adjacent normal tissues were gathered from patients who underwent surgical lung resection at the Department of Thoracic Surgery, Xiangya Hospital, CSU. Patients did not receive any radiotherapy or chemotherapy before the lung resection operation. The tumor tissues were collected from the edge of NSCLC lesions and confirmed by at least 2 experienced pathologists. Specimens were rapidly frozen in liquid nitrogen and immediately transferred to a −80°C freezer immediately for subsequent experiments. The clinicopathological characteristics of all 80 patients were collected and analyzed.
All patients were followed up every 3 months by telephone or a visit by our research team for survival and recurrence inquiry until death or until the end of the investigation. In this study, the 5-year overall survival period (OS) was defined as the interval between the surgical lung resection date and the end date of follow-up or the date of death owing to recurrence of NSCLC and its associated complications. The 5-year disease-free survival period (DFS) was the interval between the surgical resection date and the follow-up deadline or the diagnosis of recurrence and/or metastasis of NSCLC by imaging examination.
| Cell lines and cell culture
Eight NSCLC cell lines (PC9, A549, H1299, CALU-1, H520, H1437, H460, and H1703), 293T and normal human bronchial epithelial cell lines (Beas-2b) were obtained from the Chinese Academy of Science Cell Bank (Shanghai, China). All cell lines were cultured in RPMI-1640 (Gibco, Billings, MT, USA) medium supplemented with 10% FBS (Gibco), 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco) in a humidified incubator with 5% CO 2 at 37°C.
| Statistical analysis
All statistical analyses were carried out using SPSS version 25.0 software (IBM, New York, NY, USA). The results are expressed as the mean ± SD. Student's t test was used to compare the differences between 2 groups. One-way ANOVA was used to assess the differences between 3 or more groups. The χ
2
-test was used to analyze the correlation between miR-331-3p expression and clinicopathological parameters. Spearman's rank correlation was used to determine the association between miR-331-3p and ErbB2/VAV2. The log-rank test was used to compare the patient Kaplan-Meier survival curves. The Cox proportional hazard regression model was used to determine factors that were independently associated with OS and DFS. P < .05 was considered statistically significant.
More details are described in Appendix S1.
| RE SULTS
| MicroRNA-331-3p was downregulated in NSCLC tissues and inversely associated with prognosis
To explore the expression level of miR-331-3p in NSCLC tissues, we evaluated the expression of miR-331-3p in 80 pairs of frozen NSCLC tumor tissues and adjacent normal lung tissues, which were obtained at least 5 cm away from the tumor edge, by quantitative RT-PCR (qRT-PCR). Our results showed that the expression level of miR-331-3p was significantly lower in NSCLC tumor tissues than in adjacent normal tissues. Among the 80 patients, miR-331-3p expression in 45 of the patients (56.3%) was at least 50% lower in tumor tissues than in the matching normal lung tissues ( Figure 1A ). The overall expression data showed that normal lung tissues had a nearly 2-fold higher miR-331-3p level than that of adjacent tumor tissues (−0.97 ± 1.52 vs −2.02 ± 1.52, P < .0001; Figure 1B ).
Patients were then divided into 2 groups according to the relative miR-331-3p expression level in tumor tissues (log 2 fold change of tumor tissues/adjacent normal tissues ≤−1 or log 2 fold change >−1), and clinicopathological data of these patients were collected. The expression of miR-331-3p in NSCLC tumor tissues was significantly inversely correlated with lymphatic metastasis and clinical TNM stage (Table 1) . Patients who had a lower miR-331-3p expression in tumor tissues had a higher probability of lymphatic metastasis and a more advanced TNM classification.
F I G U R E 1 Expression level of microRNA (miR)-331-3p in non-small-cell lung cancer (NSCLC) tumor and adjacent normal tissues and its clinical significance. A, Relative expression level of miR-331-3p in NSCLC tumor tissues from 80 patients. B, RT-PCR results showed that the overall expression level of miR-331-3p in NSCLC tumor tissues was significantly higher than in adjacent normal tissues. C,D, Metastatic or advanced TNM stage NSCLC tumors had lower miR-331-3p expression levels compared with those of nonmetastatic or early TNM stage NSCLC tumors. E,F, Kaplan-Meier analysis showed that the 5-y overall survival and disease-free survival for NSCLC patients with low miR-331-3p levels were significantly shorter than those of patients with high miR-331-3p levels. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. HR, hazard ratio could be an independent prognostic marker for NSCLC patients.
The multivariate survival analysis data showed that tumor differentiation, clinical TNM stage, and miR-331-3p expression reached significance for the OS of NSCLC patients, and clinical TNM stage and miR-331-3p expression reached significance for diseasefree survival (Table 2) . Taken together, our results showed that miR-331-3p was remarkably downregulated in NSCLC tumor tissues and had an inverse correlation with lymphatic metastasis and clinical TNM stage. MicroRNA-331-3p expression was correlated with OS and DFS of NSCLC patients and could act as an independent prognostic marker for NSCLC patients.
| MicroRNA-331-3p inhibited migratory capacity, metastatic ability, and EMT activation of NSCLC cells
The clinicopathological statistics showed a remarkable relationship between miR-331-3p expression and metastasis. Therefore, we evaluated the function of miR-331-3p on the metastatic capacity in NSCLC cells. First, we examined miR-331-3p expression in NSCLC cell lines (PC9, A549, H1299, CALU-1, H520, H1703, H1437, and H460) and a normal bronchus epithelial cell line (Beas-2b). Our results showed that NSCLC cells had significantly lower expression of miR-331-3p compared with normal bronchus cells. Among them, A549 (with the lowest miR-331-3p expression) and H1299 (with the highest miR-331-3p expression) were selected for further assays ( Figure 2A ). These 2 cell lines were infected with lentivirus to either cause overexpression or knockdown of miR-331-3p expression. Together, these results indicated that miR-331-3p acts as an EMT suppressor and impairs the migratory and metastatic capacity of tumor cells in NSCLC.
| MicroRNA-331-3p suppressed tumor metastasis of NSCLC cells in vivo
After identifying the inhibitory effect of miR-331-3p on NSCLC cell migration and invasion in vitro, we examined whether miR-331-3p
had an impact on NSCLC metastasis in vivo. MicroRNA-331-3p-overexpressing A549 and NC cells were injected into the tail vein of nude mice. After 28 days, all mice underwent bioluminescence imaging and were killed for the next assays (Figure 3) . Our results showed that miR-331-3p-overexpressing A549-injected mice had weaker luminescence intensity compared with those injected with NC cells (0.023 ± 0.004 vs 0.053 ± 0.006; P < 0.05) ( Figures 3D,E, and S2 ). The lungs of killed mice were collected, and the metastatic nodes were counted. The number of intrapulmonary metastatic nodes in NC mice was significantly higher than that of the miR-331-3p overexpression group (15.00 ± 1.87 vs 3.25 ± 1.09; P < 0.05) ( Figure 3A-C) . The immunohistochemistry results showed that the metastatic nodes from the miR-331-3p group had noticeably lower expression of ErbB2 and VAV2 compared with those of the NC ( Figure 3A ).
| Both ErbB2 and VAV2 are direct targets of miR-331-3p
To gain further insight into the molecular mechanisms by which miR-331-3p regulates NSCLC cell migration, we used 4 miRNA target databases (miRDB, 18 miRWalk, 19 TargetScan, 20 and miRTarBase 21 ) to predict the putative targets of miR-331-3p. When we combined the results of the 4 databases, 23 genes were identified as miR-331-3p target candidates ( Figure 4A , Table S1 ). Among them, carcinogenesis-related genes such as ErbB2 and VAV2 were of special interest to us. ErbB2 and VAV2 are canonical oncogenes, and bioinformatic showed significantly decreased luciferase activity compared with the WT constructs. In contrast, this repression was not observed with the transfection of the Mut constructs. These phenomena were observed in both the ErbB2 and VAV2 targeted assays ( Figure 4C ).
Thus, the luciferase assays confirmed the direct binding of the ErbB2
and VAV2 3′-UTR to the seed region of miR-331-3p.
Furthermore, western blot analysis was carried out, and the results showed that both ErbB2 and VAV2 were dramatically sup- We found an inverse correlation between miR-331-3p and ErbB2/ VAV2 expression in NSCLC tumor tissues (ErbB2, r = −0.435, P < .0001; VAV2, r = −0.2774, P = 0.0127; Figure 4F ,G). Taken together, our data indicated that both ErbB2 and VAV2 were direct targets of miR-331-3p.
| Biological functions of miR-331-3p driven by ErbB2/VAV2 inhibition
To investigate whether miR-331-3p inhibited NSCLC cell metastasis by mediating ErbB2 and VAV2, we promoted or repressed ErbB2 and 
| MicroRNA-331-3p inhibited EMT of NSCLC cells through the ErbB2/VAV2/Rac1/PAK1/β-catenin signaling pathway
In previous experiments, we confirmed that miR-331-3p exerted its antimetastatic function by targeting ErbB2 and VAV2. ErbB2 is a well-studied oncogene and has been proved to be a Rac1 activator in breast cancer 22 and gastric cancer, 23 but its Rac1 activator function in NSCLC is not fully understood. VAV2 is also known as a direct activator of Rac1, 24, 25 and has been proved to form a complex with ErbB2. 26, 27 Taken together, we hypothesized that miR-331-3p
suppressed the migratory ability of NSCLC by targeting ErbB2 and VAV2 through Rac1 signaling. To confirm this hypothesis, we evaluated the colocalization of ErbB2 and VAV2 by immunofluorescence. Our results showed that ErbB2 and VAV2 were colocalized in the cytoplasm, and ErbB2 was also observed in the cell nucleus ( Figure 6A ). Then, coimmunoprecipitation was carried out to confirm the direct interaction of ErbB2/VAV2/Rac1 in NSCLC cells. Our data showed that ErbB2 directly bound to VAV2 and Rac1 ( Figure 6B,D) . 
| D ISCUSS I ON
Non-small-cell lung cancer has become one of the deadliest malignancies in the world, but the molecular mechanisms involved in NSCLC development are not fully understood. Recent studies revealed that miRNAs play vital roles in the tumorigenesis and progression of NSCLC. 28 In the present study, we focused on the antimetastatic function of miR-331-3p in NSCLC. The abnormal expression of miR-331-3p has been found in many types of carcinomas, but the evidence on its biological functions in the tumorigenesis of these cancers is conflicting. Our previous study showed that miR-331-3p promotes proliferation and metastasis of hepatocellular carcinoma, 15 and other researchers found similar effects of miR-331-3p in pancreatic cancer. 14 However, other researchers discovered antitumor functions of miR-331-3p in urothelial cancer, 29 gastric cancer, 16 and cervical cancer. 17 The functions of miR-331-3p in NSCLC were also ambiguous, 30, 31 reported that miR-331-3p has several targets in different cancers, such as PHLPP in hepatocellular cancer, 14 ST7L in pancreatic cancer 14 and NRP2 in cervical cancer. 17 ErbB2 was also reported to be a target of miR-331-3p, 16 but the signaling pathway that was regulated by miR-331-3p that targeted ErbB2 was unknown. Our results confirmed the regulation of miR-331-3p on ErbB2 and discovered that VAV2 was a novel direct target of miR-331-3p.
ErbB2 (HER2) was identified as a classical oncogene that promotes tumorigenesis in many malignancies, especially breast cancer, and the involvement of ErbB2 in NSCLC has also been known for many years. 32, 33 However, clinical studies targeting ErbB2 mutations have yielded disappointing results. Elevated ErbB2 expression was found in many NSCLC patients, but the role of ErbB2 overexpression in lung cancer remains unclear. 34 There are various pathways that are regulated by ErbB2 that are involved in EMT, migration, and invasion of cancers. Among them, Rac1 activation-induced migratory enhancement by ErbB2 was reported in breast cancer and ovarian tumor cells. 26, 27 The VAV family of proteins is a group of well-studied guanine nucleotide exchange factors for Rho GTPases, and VAV2 is a widely expressed member of this group. 24, 35 Rac1 was proven to be the most important Rho GTPase target of VAV2, and ErbB2 was confirmed to form F I G U R E 5 Rescue assays confirmed that ErbB2 and VAV2 were functional targets of microRNA (miR)-331-3p in A549 cells. A, ErbB2 and VAV2 expression in the miR-331-3p and ErbB2/VAV2 mimic-cotransfected A549 cells. B-E, Representative photographs and quantification of Transwell and wound healing assays in A549 cells cotransfected with miR-331-3p and ErbB2/VAV2 vectors. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. HPF, high-power field; NC, negative control a complex by binding with VAV2 and Rac1; activated Rac1 promoted the phosphorylation of PAK1, which regulated the migration and invasion of cancer cells. 26 To date, this pathway has not been proven in NSCLC. Our research first found that both ErbB2 and VAV2 were direct targets of miR-331-3p and that miR-331-3p
functions not by degrading target mRNAs but by suppressing the translation of ErbB2/VAV2 mRNAs. Moreover, we first indicated that miR-331-3p exerted its antimigration function in NSCLC by direct regulation of the ErbB2/VAV2/Rac1 pathway.
The EMT process comprises a spectrum of intermediate states between epithelial and mesenchymal phenotypes and plays a critical role in the invasion and metastasis of lung cancer. 28, 36, 37 In this study, we examined key biomarkers of EMT, such as E-cadherin, N- 
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